NET CONNECT Update from ASCO, AACR and WCGIC 2020
NET CONNECT has summarised highlights from ASCO 2020, AACR 2020 and WCGIC 2020 virtual meetings for you
Highlights from the abstracts: Efficacy and safety of surufatinib (ASCO), AGITG control NET Study (ASCO), DNA-PK inhibitor, M3814 (AACR) and Young adults with neuroendocrine tumours present high rate of pathogenic germline variants in cancer predisposing genes (WCGIC) by Dr. Aman Chauhan, University of Kentucky’s Markey Cancer Center, (NCI Designated Cancer Center), Kentucky, USA
DOWNLOAD THE SLIDES
Hello on behalf of CORONARY CONNECT my name is Jan Přeček. I'm a cardiologist from the University Hospital Olomouc in the Czech Republic.
I'd like to talk about safety of low levels of LDL cholesterol (LDL-C).
LDL-C as a Risk Factor
Elevated LDL-C is a clearly established major risk factor for the development of atherosclerotic cardiovascular disease.
Risk reduction of atherosclerotic cardiovascular disease is proportional to the absolute and relative LDL-C reduction achieved.
In other words, there seems to be no LDL-C threshold, below which no further atherosclerotic cardiovascular disease prevention can be achieved.
Please respond on a scale of 1 to 5 (5=strongly agree).